José Medina Echeverz

José Medina Echeverz has extensive work experience in the field of immunology and preclinical research. José is currently the Head of In Vivo Pharmacology at Affimed since November 2021. Prior to this, they worked at Bavarian Nordic for six years, where they held the position of Manager of Immunology Research from April 2019 to November 2021. Before that, they were a Senior Scientist at Bavarian Nordic from September 2015 to March 2019, during which they played a key role in setting up the Immuno-Oncology Preclinical Research program.

José also worked as a Postdoctoral Fellow at the National Cancer Institute from July 2012 to August 2015, focusing on the role of tumor-induced myeloid cells in the liver microenvironment and the interplay between tumor-derived factors and immune suppression. Prior to their time at the National Cancer Institute, José worked as a Research Fellow at the Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, where they conducted research on R&D of apolipoprotein-based molecular scaffolds and the impact of adeno-associated virus as gene therapy vectors on preclinical models of HBV and colon cancer metastases. José also worked as a PhD Graduate Student at CIMA, with a focus on developing therapeutic regimes combining chemotherapy and immunotherapy to boost antitumor immunity.

José Medina Echeverz completed their education in a chronological order. From 2001 to 2007, they attended the University of Navarra, where they earned a Bachelor of Science degree in Biochemistry. During this time, the specific field of study that they focused on is not indicated. Later on, from 2005 to 2006, they also attended The Philipp University of Marburg, although the degree name and field of study are not provided. Subsequently, from 2007 to 2011, they pursued a Doctor of Philosophy (PhD) degree at the University of Navarra, specializing in the fields of Gene Therapy and Hepatology.